Scientists have harnessed powerful data analysis tools and three-dimensional studies of genomic geography to implicate new risk genes for osteoporosis, the chronic bone-weakening condition that affects millions of people. Knowing the causative genes may later open the door to more effective treatments.
John M. Maris, MD, is leading a pediatric immuno-oncology Center for Discovery and Development of Optimal Immunotherapeutic Strategies for Childhood Cancers with support from the NCI Moonshot Initiative.
National Childhood Cancer Awareness Month is coming to a close, but new research endeavors are continuing the momentum and driving toward better treatment options. Hyundai Hope On Wheels awarded two pediatric cancer investigators at Children's Hospital of Philadelphia research grants during a Celebration of Life Gala held Sept. 27 in Philadelphia.
September marks National Childhood Cancer Awareness Month, and this year at Children's Hospital of Philadelphia, we kick-started the commemorative period on the heels of exciting news about breakthroughs in pediatric cancer immunotherapy research.
Researchers from the Children's Oncology Group (COG) have developed a new standardized dosing method for anticancer drugs in infants to use across all COG clinical trials. This unified method, based on dose banding and organized into tables for different drugs and dose levels, will address the limitations and variability that researchers can encounter in current methods.